Clinical trials: Cirrhosis, Liver
Portal Hypertension
A Novel Spleen-dedicated Stiffness Measured by FibroScan to Evaluate Cirrhotic Portal Hypertension (CHESS2105)
Portal hypertension contributed to the main complications of liver cirrhosis. Currently, hepatic venous pressure gradient (HVPG) was the reference standard for evaluating portal pressure in patients with cirrhosis.
- Trial name
- NCT05052892
- Testing
- Hepatic venous pressure gradient
- Where
- 3 sites in China
- Volunteers
- 1,000 people
- Sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
Liver Cirrhosis, Periapical Lesions
Oral Health Status in Patients With Cirrhosis and Effect of Dental Treatment on MELD Score of Cirrhosis Patients
It has been found that there is an association between prevalence of odontogenic infection and systemic diseases.Cirrhosis has also been associated with poor oral health status.Treating those patients accordingly can help in…
- Trial name
- NCT04399512
- Testing
- Nonsurgical root canal treatment
- Where
- India
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Postgraduate Institute of Dental Sciences Rohtak
Portal Hypertension, Chronic Liver Disease
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
This prospective multicentre observational reliability study will determine how much a repeated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement differs from the first measurement in the same patient…
- Conditions
- Portal Hypertension, Chronic Liver Disease, Liver Cirrhosis
- Trial name
- REPEAT-PPG (NCT07877298)
- Testing
- Repeated EUS-Guided Portal Pressure Gradient Measurement
- Where
- 5 sites in Belgium, Canada and 2 more
- Volunteers
- 150 people
- Sponsor
- University Hospital Muenster
Liver Cirrhosis
Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects…
- Trial name
- NCT01904409
- Testing
- Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet
- Where
- 120 sites in United States, Russia
- Volunteers
- 420 people
- Sponsor
- Bausch Health Americas, Inc.
Ascites, Cirrhosis
Improving Performance of Paracentesis in Medical Residency Training
The investigators hypothesize that there is significant variability in management of patients with ascites despite guidelines provided by the American Association for the Study of Liver Diseases, the professional organization…
- Trial name
- NCT01403987
- Testing
- Residency Program Teaching, Lecture, Pocket Card Reference
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Boston Medical Center
Liver Fibrosis, Chronic Liver Disease
Pirfenidone and Advanced Liver Fibrosis.
Pirfenidone (PFD), an oral antifibrotic drug with anti-inflammatory and anti-oxidant properties, has been granted marketing authorization by the European Medicine Agency and FDA, for the treatment of idiopathic pulmonary fibrosis…
- Trial name
- PROMETEO (NCT04099407)
- Testing
- Pirfenidone, Standard of care
- Where
- Mexico
- Volunteers
- 122 people
- Sponsor
- Grupo Mexicano para el Estudios de las Enfermedades Hepaticas
Spontaneous Bacterial Peritonitis, Hepatorenal Syndrome
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
Advanced liver disease and low ascitic fluid protein concentration have been identified as risk factors for spontaneous bacterial peritonitis in cirrhosis.
- Conditions
- Spontaneous Bacterial Peritonitis, Hepatorenal Syndrome, Cirrhosis
- Trial name
- NCT00359853
- Testing
- Oral norfloxacin
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Hospital Clinic of Barcelona
Cirrhosis
Thrombin Generation Test in Patient With Liver Cirrhosis
Cirrhotic patients are patients with high morbidity and mortality, it is very important for determining the prognosis of these patients. The importance increases when these patients waiting for a liver transplant.
- Trial name
- NCT02484534
- Where
- Israel
- Volunteers
- 36 people
- Sponsor
- HaEmek Medical Center, Israel
Primary Biliary Cirrhosis, Hypercholesterolemia
Safety and Efficacy of Long-Term Treatment With Atorvastatin in Patients With Primary Biliary Cirrhosis
Primary biliary cirrhosis (PBC) is frequently associated with hypercholesterolemia and possibly with an increased cardiovascular morbidity and mortality.
- Trial name
- NCT00844402
- Testing
- Atorvastatin
- Where
- Austria
- Volunteers
- 40 people
- Sponsor
- Medical University of Graz
Hepatocellular Carcinoma
Impact of Y90 Radiation Segmentectomy on HCC
The aim of this pilot study is to assess the efficacy of radiation segmentectomy with Theraspheres in patients with unresectable hepatocellular carcinoma that would qualify for thermal ablation as per the BCLC guidelines, but are…
- Trial name
- NCT03248375
- Testing
- Radiation Segmentectomy
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Liver Fibrosis, Cirrhosis
FibroTouch Non-invasive Evaluation of Liver Fibrosis and Cirrhosis
This prospective and multicenter study is to determine the diagnostic performance (accuracy, specificity and sensitivity) of transient elastography (FibroTouch) for liver fibrosis assessment in chronic hepatitis B (CHB) patients…
- Conditions
- Liver Fibrosis, Cirrhosis, Chronic Hepatitis B
- Trial name
- NCT02476695
- Testing
- FibroTouch Examination, FibroScan Examination, Ultrasonic B Examination
- Where
- 15 sites in China
- Volunteers
- 412 people
- Sponsor
- Wuxi Hisky Medical Technology Co Ltd
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis
Isocaloric Navy-Bean Substitution in Adults With MASLD
This study is a 24-week randomized crossover feasibility trial evaluating an isocaloric navy-bean dietary substitution in 40 adults with metabolic dysfunction-associated steatotic liver disease (MASLD) and intermediate-stage…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Trial name
- BEAN-MASLD (NCT07730853)
- Testing
- Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Liver Fibrosis, Hepatic Cirrhosis
Study of AZD2389 Safety, Tolerability, and Pharmacodynamics in Adults With Steatotic Liver Disease and Advanced Fibrosis
The purpose of this study is to evaluate the safety, tolerability, and pharmacodynamic effects of AZD2389 in adult participants with steatotic liver disease (SLD) and advanced fibrosis.
- Trial name
- BRAVO (NCT07610837)
- Testing
- AZD2389
- Where
- 22 sites in United States, Puerto Rico
- Volunteers
- 104 people
- Sponsor
- AstraZeneca
Liver Cirrhosis
Exploring the Mechanisms of Postoperative Delirium in Cirrhotic Patients Through Multi-Omics Integrative Analysis
This study looks at memory problems after surgery in people with liver disease. We want to know how often these problems happen and what might cause them. The main question it aims to answer is: 1.
- Trial name
- NCT07012434
- Volunteers
- 133 people
- Sponsor
- Sichuan Provincial People's Hospital
Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient
Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System
The thrombin generation test is a global test for the study of coagulation that allows the fine study of the balance between procoagulant and anticoagulant factors.
- Conditions
- Patients Without a Medical History of Thrombosis or Hemorrhage, Hemophilic Patient, Patient With FV Leiden Mutation, Patient With Cirrhosis
- Trial name
- EVIGE (NCT05422157)
- Where
- France
- Volunteers
- 71 people
- Sponsor
- University Hospital, Clermont-Ferrand
Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as evidenced by histopathological improvements in fibrosis in adult NASH subjects…
- Conditions
- Nonalcoholic Steatohepatitis (NASH), Fibrosis, Liver, NAFLD
- Trial name
- ASCEND (NCT05402371)
- Testing
- Rencofilstat
- Where
- 41 sites in United States, France and 1 more
- Volunteers
- 120 people
- Sponsor
- Hepion Pharmaceuticals, Inc.
MAFLD, Liver Fibrosis
Incidence of Liver Disease-Related Outcomes in People With HIV
Antiretroviral therapy can effectively control the replication of HIV, prolong the lifespan of patients infected with HIV, and improve their quality of life.At the same time, non-AIDS-related diseases such as diabetes and chronic…
- Conditions
- MAFLD, Liver Fibrosis, MASH, HIV
- Trial name
- PWH (NCT06940375)
- Testing
- Abdominal ultrasound , Fibroscan and body composition analysis examination
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Shanghai Public Health Clinical Center
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
MASLD in Type 2 Diabetes in Primary Care - a Follow-up Study
The goal of this observational study is to understand how metabolic dysfunction-associated steatotic liver disease (MASLD) changes over time in individuals with type 2 diabetes who previously participated in the EPSONIP study.
- Conditions
- MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis, Advanced Fibrosis, Sarcopenia
- Trial name
- EPSOMIP2 (NCT07312136)
- Where
- Sweden
- Volunteers
- 317 people
- Sponsor
- Linkoeping University
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Hepatitis, Hepatitis B, Chronic
Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis
This research study was conducted to compare the safety and effectiveness of the investigational medication, LdT (Telbivudine) versus Lamivudine, a drug currently approved by the US, European and Asian Health Authorities for the…
- Conditions
- Hepatitis, Hepatitis B, Chronic, Cirrhosis
- Trial name
- NCT00076336
- Testing
- Telbivudine, Lamivudine
- Where
- 28 sites in United States, Australia and 19 more
- Volunteers
- 232 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.